Keros Therapeutics, Inc. (NASDAQ:KROS) Triggers Short-Term Retracement Amid Liquidity Repricing
![]() |
Keros shows concentrated technical weakness despite ample cash and a recent milestone that recalibrates near-term funding. Fundamentals reflect ongoing development expense declines but persistent losses, leaving valuation labeled over-valued by WMDST. |









